魯抗醫藥(600789.SH):頭孢拉定膠囊通過仿製藥一致性評價
格隆匯1月8日丨魯抗醫藥(600789.SH)公佈,近日,公司收到國家藥品監督管理局頒發的關於頭孢拉定膠囊的《藥品補充申請批件》(批件號:2019B04626),該藥品通過仿製藥質量和療效一致性評價。
頭孢拉定膠囊屬於頭孢菌素類藥物,根據其抗菌譜、抗菌活性、對β-內酰胺酶的穩定性以及腎毒性的不同,目前分為四代。頭孢拉定屬於第一代頭孢菌素,本品通過抑制細胞壁的合成,使細胞內容物膨脹至破裂溶解,從而達到殺菌作用,對革蘭陽性菌(包括耐青黴素的金黃色葡萄球菌)相當有效,對革蘭陰性菌產生的β-內酰胺酶的穩定性較差。適用於敏感菌所致的急性咽炎、扁桃體炎、中耳炎、支氣管炎和肺炎等呼吸道感染、泌尿生殖道感染及皮膚軟組織感染等。本品為口服制劑,不宜用於嚴重感染。
2019年1-9月份,頭孢拉定膠囊國內銷售額約為3.26億元人民幣,公司該產品的銷售收入為8231.62萬元。該藥品開展一致性評價工作以來,公司累計研發投入約為800萬元人民幣(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.